Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm NCT07295132

RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)

A Randomized Clinical Trial Evaluating the Role of Secondary Cytoreductive Surgery Following Neoadjuvant Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: Patient Selection Informed by CA-125 Response Dynamics During Chemotherapy (RESCUE Study)

Sponsor: Asan Medical Center

Conditions Ovarian Cancer Recurrent Platinum Sensitive Ovarian Cancer

Interventions Platinum Based Chemotherapy Secondary cytoreductive surgery

Updated 1 time since 2026 Last updated: Dec 16, 2025 Started: Dec 15, 2025 Primary completion: Nov 15, 2029 Completion: Nov 15, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07295132, this PHASE2 trial focuses on Ovarian Cancer Recurrent and Platinum Sensitive Ovarian Cancer and remains actively recruiting participants. Sponsored by Asan Medical Center, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Asan Medical Center
Korean Gynecologic Oncology Group

Data source: Asan Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.